Histological guided treatment in paediatric patients presenting with severe left ventricular dysfunction

Other authors

Institut Català de la Salut

[Dolader P, Juzga Corrales DC] Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cardiologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Esmel Vilomara R] Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cardiologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Paediatric Cardiology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. [Daina C, Fernandez E] Unitat de Cures Intensives Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Izquierdo Blasco J] Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat de Cures Intensives Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Garrido Pontnou M, Navarro A, Camacho J] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Betrian Blasco P, Roses Noguer F, Gran F] Universitat Autònoma de Barcelona, Barcelona, Spain. Servei de Cardiologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-11-25T13:28:13Z

2025-11-25T13:28:13Z

2025-09-18



Abstract

Dilated cardiomyopathy; Endomyocardial biopsy; Myocarditis


Cardiomiopatia dilatada; Biòpsia endomiocàrdica; Miocarditis


Cardiomiopatía dilatada; Biopsia endomiocárdica; Miocarditis


Differential diagnosis in children presenting with dilated cardiomyopathy and severe cardiac dysfunction is challenging. In our hospital, a protocol was established in 2015 in which endomyocardial biopsy (EMB) was performed in selected patients and treatment was guided by biopsy results. The study aims to describe our experience with this diagnostic and therapeutic strategy. We performed a unicenter paediatric ambispective study that include patients with dilated cardiomyopathy and severe cardiac dysfunction (left ventricular ejection fraction (LVEF) < 35%) in whom EMB was performed and treatment was prescribed based on EMB results from February 2015 to December 2024. 23 patients (24 episodes) were included. 15 patients had a complete recovery, 5 patients had a partial response to treatment and 4 had no response to treatment. Patients were divided into two groups, those with complete recovery (15) and those without complete recovery (9). No differences were observed in sex, age, clinical presentation, need for Extracorporeal Membrane Oxygenation (ECMO) or echocardiogram parameters. Complete recovery was associated with a higher degree of inflammation on EMB (p < 0.001), necrosis (= 0.007) and oedema (p = 0.036), negative genetic testing (p < 0.001), higher troponin values (p = 0.015) and positive viral PCR in myocardial tissue (p < 0.001). Conclusion: EMB is a valuable tool for diagnosis and treatment of paediatric patients presenting with dilated cardiomyopathy. Factors associated with a favourable response to therapy include: intense inflammatory infiltrate in EMB, oedema, necrosis, positive viral PCR found in the myocardium, high elevation of troponins and negative genetic testing. What is Known: • Differential diagnosis in paediatric patients presenting with severe dysfunction is challenging • EMB remains the gold standard technique for the diagnosis of myocarditis and can help to guide treatment What is New: • EMB guided treatment my benefit paediatric patients with inflammatory cardiomyopathy. • Factors associated with a favourable response to treatment in patients presenting with severe cardiac dysfunction include: intense inflammatory infiltrate in EMB, oedema, necrosis, positive viral PCR in the myocardium, high elevation of troponins and negative genetic testing. • Positive genetic testing was observed in some patients with inflammatory cardiomyopathy. In our opinion, genetic testing should be considered in all patients presenting with severe dysfunction. • Interferon β combined with corticosteroids may offer a beneficial treatment approach in patients with Parvovirus B19-induced myocarditis.


Open Access Funding provided by Universitat Autonoma de Barcelona.

Document Type

Article


Published version

Language

English

Publisher

Springer

Related items

European Journal of Pediatrics;184(10)

https://doi.org/10.1007/s00431-025-06424-x

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)